OW-DOSE KETAMINE AS ADJUVANT TREATMENT TO MORPHINE IN NEUROPATHIC CANCER PAIN. - Keta-1

Haukeland University hospital0 个研究点开始时间: 2012年6月5日最近更新: 2013年1月21日

适应症

试验速览

暂无简介。

•Age 18-70 years.
•Patients are admitted to hospital
•Cancer pain judged to have a neuropathic component.
•Clinically normal renal and hepatic function.
•Patients are able to cooperate and understand information.
•”Worst” pain at rest or on movement is 5 or more (NRS 0-10).
•The pain is currently treated with continuous subcutaneous morphine infusion.
•The daily morphine dose is =48mg/24 hours and a 30% increase in the daily dose has not provided sufficient pain relief.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 20
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•Reduced renal or hepatic function.
•Suspicion of morphine toxicity (sedation, hallucination, myoclonus, increasing pain).
•Increased intracranial pressure (suspicion of cerebral metastases) or cerebral metastases.
•Unable to cooperate/ understand information.
•”Worst” pain at rest or on movement < 5 on NRS.
•Current treatment with other opioids than morphine.
•The patient is undergoing radiotherapy in the pain area, or has received radiotherapy in the pain area within the last four weeks.
•Changes in the use of analgesics (paracetamol, NSAIDS), adjuvant drugs (antidepressants, antiepileptics, corticosteroids, muscle relaxants) or their dosages less than 2 days prior to inclusion or during the study period.

发起方

Haukeland University hospital